Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Agurto-Arteaga, Andres, Poma-Acevedo, Astrid, Rios-Matos, Dora, Choque-Guevara, Ricardo, Montesinos-Millán, Ricardo, Montalván, Ángela, Isasi-Rivas, Gisela, Cauna-Orocollo, Yudith, Cauti-Mendoza, María de Grecia, Pérez-Martínez, Norma, Gutierrez-Manchay, Kristel, Ramirez-Ortiz, Ingrid, Núñez-Fernández, Dennis, Salguedo-Bohorquez, Mario I., Quiñones-Garcia, Stefany, Fernández Díaz, Manolo, Guevara Sarmiento, Luis A., Zimic, Mirko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157249/
https://www.ncbi.nlm.nih.gov/pubmed/35664008
http://dx.doi.org/10.3389/fimmu.2022.881604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157249/
https://www.ncbi.nlm.nih.gov/pubmed/35664008
http://dx.doi.org/10.3389/fimmu.2022.881604

Ejemplares similares